![Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity - Wiley Online Library Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/6a90407c-caf4-43d8-89a8-967ad4ccf7a9/cbdv201700533-fig-0004-m.jpg)
Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity - Wiley Online Library
![Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity - Wiley Online Library Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/d43224ff-60b2-492b-9832-195bce3c9c47/cbdv201700533-fig-0003-m.jpg)
Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity - Wiley Online Library
![Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.8b01040/asset/images/large/jm-2018-01040m_0001.jpeg)
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
![A, Selectivity profiles of GNF-2, GNF-5, and ABL-001 in contrast to two... | Download Scientific Diagram A, Selectivity profiles of GNF-2, GNF-5, and ABL-001 in contrast to two... | Download Scientific Diagram](https://www.researchgate.net/profile/Jill-Jones-8/publication/342573533/figure/fig2/AS:1003064152584195@1616160538729/A-Selectivity-profiles-of-GNF-2-GNF-5-and-ABL-001-in-contrast-to-two-non-allosteric_Q320.jpg)
A, Selectivity profiles of GNF-2, GNF-5, and ABL-001 in contrast to two... | Download Scientific Diagram
![Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.8b01040/asset/images/large/jm-2018-01040m_0014.jpeg)
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
![Details of the molecular interactions between GNF-2 and ABL001 and the... | Download Scientific Diagram Details of the molecular interactions between GNF-2 and ABL001 and the... | Download Scientific Diagram](https://www.researchgate.net/publication/344252151/figure/fig3/AS:983895549935621@1611590387775/Details-of-the-molecular-interactions-between-GNF-2-and-ABL001-and-the-myristate-binding.png)